Basel Medical Group Ltd Reaffirms Strong Financial Position Amid Market Volatility
Basel Medical Group Ltd (NASDAQ: BMGL) has issued a statement addressing recent share price volatility, emphasizing the company's strong financial fundamentals. CEO Dr Darren Chhoa reassured stakeholders that the company's underlying performance remains robust, highlighting new contract wins in the supply chain sector through its subsidiaries. The company maintains it is on track with its acquisition growth strategy and believes the recent stock price decline does not reflect BMGL's intrinsic value. Management emphasized their continued focus on operational execution and disciplined capital management.
Basel Medical Group Ltd (NASDAQ: BMGL) ha rilasciato una dichiarazione per commentare la recente volatilità del prezzo delle azioni, sottolineando la solidità dei fondamentali finanziari dell'azienda. Il CEO, Dr Darren Chhoa, ha rassicurato gli stakeholder affermando che le performance sottostanti dell'azienda rimangono solide, evidenziando nuove acquisizioni di contratti nel settore della catena di approvvigionamento tramite le sue filiali. L'azienda conferma di essere in linea con la strategia di crescita tramite acquisizioni e ritiene che il recente calo del prezzo delle azioni non rispecchi il valore intrinseco di BMGL. La direzione ha ribadito il continuo impegno nell'esecuzione operativa e nella gestione disciplinata del capitale.
Basel Medical Group Ltd (NASDAQ: BMGL) ha emitido un comunicado para abordar la reciente volatilidad en el precio de sus acciones, destacando los sólidos fundamentos financieros de la empresa. El CEO, Dr. Darren Chhoa, tranquilizó a los interesados asegurando que el desempeño subyacente de la compañía sigue siendo robusto, resaltando nuevas adjudicaciones de contratos en el sector de la cadena de suministro a través de sus subsidiarias. La empresa mantiene que está avanzando según su estrategia de crecimiento mediante adquisiciones y considera que la reciente caída en el precio de las acciones no refleja el valor intrínseco de BMGL. La dirección enfatizó su enfoque continuo en la ejecución operativa y la gestión disciplinada del capital.
Basel Medical Group Ltd (NASDAQ: BMGL)는 최근 주가 변동성에 대해 성명을 발표하며 회사의 견고한 재무 기초를 강조했습니다. CEO인 Dr. Darren Chhoa는 회사의 기본 실적이 여전히 탄탄하다고 이해관계자들을 안심시키며, 자회사들을 통한 공급망 부문에서의 신규 계약 수주를 부각시켰습니다. 회사는 인수 성장 전략이 계획대로 진행 중임을 유지하며, 최근 주가 하락이 BMGL의 내재 가치를 반영하지 않는다고 믿고 있습니다. 경영진은 운영 실행과 엄격한 자본 관리를 지속적으로 중점적으로 추진하고 있음을 강조했습니다.
Basel Medical Group Ltd (NASDAQ: BMGL) a publié une déclaration pour répondre à la récente volatilité du cours de ses actions, en soulignant la solidité des fondamentaux financiers de l'entreprise. Le PDG, Dr Darren Chhoa, a rassuré les parties prenantes en affirmant que la performance sous-jacente de la société reste robuste, mettant en avant de nouveaux contrats remportés dans le secteur de la chaîne d'approvisionnement via ses filiales. L'entreprise maintient qu'elle suit sa stratégie de croissance par acquisitions et estime que la récente baisse du cours de l'action ne reflète pas la valeur intrinsèque de BMGL. La direction a insisté sur son engagement continu envers l'exécution opérationnelle et une gestion rigoureuse du capital.
Basel Medical Group Ltd (NASDAQ: BMGL) hat eine Stellungnahme zur jüngsten Volatilität des Aktienkurses veröffentlicht und dabei die starken finanziellen Grundlagen des Unternehmens betont. CEO Dr. Darren Chhoa versicherte den Stakeholdern, dass die zugrunde liegende Performance des Unternehmens robust bleibt, und hob neue Vertragsabschlüsse im Bereich der Lieferkette über die Tochtergesellschaften hervor. Das Unternehmen hält an seiner Wachstumsstrategie durch Akquisitionen fest und ist der Ansicht, dass der jüngste Kursrückgang den inneren Wert von BMGL nicht widerspiegelt. Das Management betonte seinen fortgesetzten Fokus auf operative Umsetzung und diszipliniertes Kapitalmanagement.
- Company confirms winning new sizable contracts in supply chain sector
- Management reaffirms strong financial performance
- Company reports being on track with acquisition growth strategy
- Recent significant share price decline
- Market showing volatility in company's stock performance
Singapore, May 29, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL or the “Company”), today reaffirmed the strength of its underlying financial performance and strategic outlook, despite recent volatility in its share price.
Speaking on behalf of the Board and management team, BMGL’s Chief Executive Officer, Dr Darren Chhoa stated, “While recent movements in our share price may raise questions, I want to assure our shareholders and stakeholders that the fundamentals of BMGL remain strong and resilient. Our financial performance continues to be robust, with our subsidiaries winning new sizable contracts particularly in the supply chain, and we remain on track with our acquisition growth strategy.”
“We believe that the recent share price decline does not reflect the intrinsic value of our business nor the solid progress we’ve made. BMGL has consistently demonstrated strong operational execution, disciplined capital management, and a commitment to delivering sustainable value for shareholders.”
About Basel Medical Group Ltd
Basel Medical is a Singapore-based provider of orthopedic and trauma services, sports medicine and surgery, orthopedic procedures, as well as neurosurgical treatments. Our operations are based in Singapore, with our clinics being at 6 Napier Road, Unit #02-10/11 and Unit #03-07, Gleneagles Medical Centre. Over the last 20 years, our group has forged strong and lasting relationships with a large base of corporations, in particular those in the construction, marine and oil & gas industries, which underpin our robust business model. As an orthopedic service provider in Singapore with a track record of over 20 years, we are well-positioned to ride the wave of growth opportunities in the private healthcare industry in Singapore and across Southeast Asia driven by ageing populations, rising income levels, increasing private insurance coverage, government effort and expenditure on healthcare, growing sports participation rate and Singapore’s position as a premium destination for healthcare services in Asia. Our management and medical practitioner team comprises a roster of orthopedic and neurosurgery specialists, corporate finance and healthcare partnership specialists. Basel Medical Group Ltd serves as the holding company of our group and we conduct our operations through our operating subsidiaries based in Singapore. For more information, please visit the Company’s website: www.baselmedical.com.
Forward-Looking Statements
Certain statements in this announcement are forward-looking statements, which involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “aim”, “anticipate”, “believe”, “estimate”, “expect”, “going forward”, “intend”, “may”, “plan”, “potential”, “predict”, “propose”, “seek”, “should”, “will”, “would” or other similar expressions in this press release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s filings with the SEC.
Media Contact:
Basel Medical Group Ltd
+65 6291 9188
contact@baselmedical.com
www.baselmedical.com
FAQ
What caused the recent share price decline in Basel Medical Group (BMGL) stock?
How is Basel Medical Group (BMGL) performing financially in 2025?
What measures is Basel Medical Group (BMGL) taking to address the stock volatility?
What new contracts has Basel Medical Group (BMGL) won in 2025?
